Pharma News, 2022

Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its oncology ambitions – has the biopharma community aflutter. ...

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense drug for one of the complications of the disease transthyretin amyloidosis (ATTR) ...

Clovis Oncology has requested a withdrawal of FDA approval of Rubraca (rucaparib) for treating patients with BRCA-mutated ovarian cancer after two or more chemotherapies. ...

A new type of drug that prompts the body’s muscles to absorb excess blood sugar could revolutionize the treatment of type 2 diabetes.

Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today ann...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Verzenios (abemaciclib) for National Health Service (NHS) use in patients with hormone receptor-po...

New research led by scientists from Australia’s La Trobe University suggests proteins generated by the SARS-CoV-2 virus can form into aggregations similar to those found in the brains of patients...

Stanford researchers and their colleagues have found a molecule that suppresses appetite after intense exercise.

Walgreens is the latest US retail pharmacy giant to have a go at disrupting the clinical trials industry, with the launch of a new business unit that will tap into its reserve of patient data, as w...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non...

The U.S. Food and Drug Administration has awarded its first approval in the specific interleukin-23 inhibitor space for Crohn's disease to AbbVie's Skyrizi (risakizumab-rzaa).  ...

The U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee (PDAC) voted against Acadia Pharmaceutical’s supplemental New Drug Application (sDNA) of Nuplazid (pimavans...